PRISMA-P 2015 Checklist*

This checklist has been adapted for use with systematic review protocol submissions to BioMed Central journals from Table 3 in Moher D et al: Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic Reviews 2015 4:1

An Editorial from the Editors-in-Chief of *Systematic Reviews* details why this checklist was adapted - Moher D, Stewart L & Shekelle P: Implementing PRISMA-P: recommendations for prospective authors. *Systematic Reviews* 2016 **5**:15

*Note from corresponding author: The Prisma-P checklist is adapted to systematic reviews. The proposed study is a scoping review, thus some items of the checklist are not applicable and have not been reported. Items that have been found to be inapplicable have been marked by "N/A" in the cells of the "Line number(s)" column.

Section/topic	#	Checklist item	Information reported		Line
	#		Yes	No	number(s)
ADMINISTRATIVE IN	NFORMAT	TION			
Title					
Identification	1a	Identify the report as a protocol of a systematic review			1 - 3
Update	1b	If the protocol is for an update of a previous systematic review, identify as such		\boxtimes	N/A
Registration	2	If registered, provide the name of the registry (e.g., PROSPERO) and registration number in the Abstract			52
Authors					
Contact	3a	Provide name, institutional affiliation, and e-mail address of all protocol authors; provide physical mailing address of corresponding author			9 - 10
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review			513 - 517
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments			N/A
Support					
Sources	5a	Indicate sources of financial or other support for the review			503 - 511
Sponsor	5b	Provide name for the review funder and/or sponsor			503 - 511
Role of	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol			503 - 511



Section/topic	#	Checklist item	Information reported		Line
			Yes	No	number(s)
sponsor/funder					
INTRODUCTION					
Rationale	6	Describe the rationale for the review in the context of what is already known			58 - 142
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)			157 - 204
METHODS		The state of the s			
Eligibility criteria	8	Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report characteristics (e.g., years considered, language, publication status) to be used as criteria for eligibility for the review			249 - 307
Information sources	9	Describe all intended information sources (e.g., electronic databases, contact with study authors, trial registers, or other grey literature sources) with planned dates of coverage			216 - 243, 244-245 (data lock point)
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated			7-32 (Additional File 2)
STUDY RECORDS					
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review			309 - 311
Selection process	11b	State the process that will be used for selecting studies (e.g., two independent reviewers) through each phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis)			312 - 315, 317 - 319
Data collection process	11c	Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators			318 - 319
Data items	12	List and define all variables for which data will be sought (e.g., PICO items, funding sources), any pre-planned data assumptions and simplifications			321 - 348
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale			321 - 348
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data			N/A



Section/topic	#	Checklist item	Information reported		Line		
			Yes	No	number(s)		
		synthesis					
DATA							
Synthesis	15a	Describe criteria under which study data will be quantitatively synthesized		\boxtimes	N/A		
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data, and methods of combining data from studies, including any planned exploration of consistency (e.g., I^2 , Kendall's tau)			N/A		
	15c	Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses, meta-regression)			N/A		
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned			351 - 406		
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (e.g., publication bias across studies, selective reporting within studies)			N/A		
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (e.g., GRADE)			363 -364		

